Waldencast Acquisition Corp. (NASDAQ:WALD) announced this morning that it has added $225 million in debt to its combination with beauty brands OBAGI and Milk.
This new money comes in the form of a four-year secured first-lien made up of a $175 million term loan and a $50 million revolving loan facility with $7.5 million available to be drawn as letters of credit. JP Morgan Chase (NYSE:JPM), Santander (NYSE:SAN) and Wells Fargo (NYSE:WFC) served as joint bookrunners and lead arrangers for the facility with JPM serving as administrative agent and Credit Suisse (NYSE:CS) as documentation agent.
The combined company would now receive $1.02 billion in total proceeds as this debt joins $333 million in forward purchase agreements (FPAs), a $113 million PIPE and Waldencast’s $345 million trust before redemptions. The PIPE and FPAs already covered the $440 million collective minimum cash conditions for the two companies, but the debt further secures all of the uses that the targets had in mind.
At announcement, the parties envisaged paying out $520 million in cash consideration to selling shareholders of the two companies and this new facility is aimed at paying down and replacing all of the companies’ existing credit facilities as well. Even in a 100% redemptions scenario, the combined company is now expected to have about $94 million in new capital to work with after expenses and consideration to sellers.
Waldencast initially announced the $1.2 billion combination with OBAGI and Milk Makeup on November 15. OBAGI provides medical-grade skincare products and Milk Makeup provides clean 100% vegan cosmetics via retail stores and its native ecommerce site.
The parties have not yet set a date for a completion vote on the deal, but on June 13, Waldencast announced an agreement with Obagi and Cedarwalk pertaining to the value of and cost associated with inventory on hand. As of five business days before the special shareholder meeting, the cost of inventory will be deducted from the cash portion of the consideration payable under the Obagi merger agreement to Cedarwalk.
Obagi Hong Kong will pay Obagi and certain affiliates a royalty of 2.75% of gross sales on the specific inventory identified in the agreement that is sold during the 90 days following the completion of the transaction.
Terms Tracker for the Week Ending May 23, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Another solid week for SPAC IPO trading. Five more IPOs priced, bringing May’s total to 18 and the YTD tally to 49. That’s just eight...
Pelican Acquisition Corp. (NASDAQ:PELIU) announced the pricing of its $75 million IPO and its units began trading on the Nasdaq under the symbol “PELIU”, Friday, May 23, 2025. The new SPAC aims to combine with a technology company with a defensible market position that would benefit from being publicly traded in the US. Pelican’s management...
Cohen Circle II (NASDAQ:CCIIU) has filed for a $220 million SPAC marking the second wave of the Betsy Cohen team’s return to the market in the burgeoning 2024/2025 cycle. The new SPAC brings slightly less warrant coverage than its predecessor Cohen Circle I (NASDAQ:CCIR) with a 1/4 warrant in each of its units as opposed...
A Paradise (NASDAQ:APADU) has filed for a $200 million SPAC to get a fresh Asia-focused vehicle on the road with a leader that has steered several SPACs before. The new SPAC continues underwriter Cohen & Company’s warpath as its 15th SPAC put on file this year, with the firm’s 12th SPAC IPO debut set for...
On this week’s SPACInsider REPLAY, we revisit a 2022 conversation with Harry Sloan of the Eagle SPACs. At the time, Harry had already completed seven SPACs and was closing in on his eighth. As markets cooled and the SPAC boom waned, Harry offered a prescient take on where the market was headed—and what a “post-boom”...